Integrative transcriptomic and molecular dynamics simulations analysis identifies IL6 as a therapeutic hub gene in inflammatory arthritis.
It is inferred that levofloxacin remains an ideal therapeutic lead with favorable computational drug-binding properties and retained stability when bound to IL-6 during molecular dynamics simulation, which makes levofloxacin one of the top choices for future experimentation against inflammatory arthritis.